Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=)…
- Trial name
- NCT03492177
- Testing
- selexipag (Uptravi)
- Where
- 34 sites in United States, Belarus and 14 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
the purpose of this study is: To assess the effect of BIA 5 1058 400 mg on the PK of bosentan. To assess the effect of bosentan on the PK of BIA 5 1058
- Trial name
- NCT04991207
- Testing
- BIA 5-1058, bosentan
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Hypertension
Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to determine the effects of spironolactone on collagen markers in a large number of patients with pulmonary hypertension.
- Trial name
- NCT01468571
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor College of Medicine
Pulmonary Arterial Hypertension, Frailty
Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension
The purpose of the study is to learn more about how low-resistance training impacts frailty and the quality of life of people with pulmonary arterial hypertension (PAH).
- Trial name
- RESIST-PH (NCT06543745)
- Testing
- Low-Resistance Training
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension (PAH)
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
- Trial name
- (STOP-PAH) (NCT06872112)
- Testing
- Artesunate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Joseph C. Wu
Hypertension, Pulmonary
Pulmonary Hypertension: Assessment of Cell Therapy
The primary objective is to establish the safety of autologous progenitor cell-based gene therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to conventional treatment.
- Trial name
- PHACeT (NCT00469027)
- Testing
- eNOS transfected EPCs will be delivered via a PA line
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Northern Therapeutics
Pulmonary Hypertension
The Role of Endothelin in Pulmonary Hypertension
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
- Trial name
- NCT00759408
- Testing
- BQ-123
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Interstitial Lung Disease, COPD
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as…
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- GUARDIANLUNG (NCT04930289)
- Testing
- LungGuard, BAROGuard
- Where
- 15 sites in United States, Belgium
- Volunteers
- 3,500 people
- Sponsor
- Paragonix Technologies
Pulmonary Hypertension
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the efficacy and safety of vardenafil in the treatment of pulmonary arterial hypertension.
- Trial name
- EVALUATION (NCT00718952)
- Testing
- Vardenafil
- Where
- 10 sites in China
- Volunteers
- 60 people
- Sponsor
- Tongji University
Hypertension, Pulmonary Arterial
Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires
The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.
- Trial name
- PH-HIBA (NCT01501838)
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Hospital Italiano de Buenos Aires
Pulmonary Arterial Hypertension
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH).
- Trial name
- NCT06907693
- Testing
- CT Pulmonary Angiography Scan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Prisma Health-Upstate
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending…
- Trial name
- EPITOME-1 Ext (NCT01105117)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07143448
- Testing
- HS235
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 90 people
- Sponsor
- 35Pharma Inc., a GSK company
Pulmonary Arterial Hypertension (PAH)
Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes
This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes…
- Trial name
- NCT07082933
- Testing
- Standard medical treatment
- Volunteers
- 5,000 people
- Sponsor
- Xijing Hospital
Idiopathic Pulmonary Arterial Hypertension
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
The current aims to combine analysis of different inflammatory biomarkers and BMPR2 mutations, which are currently analyzed in each patient diagnosed with idiopathic or familial PAH, to establish an earlier diagnosis and…
- Trial name
- NCT02959723
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Arterial Hypertension
Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease
The prevalence of PAH associated with congenital systemic-to-pulmonary shunts in Western countries has been estimated to range between 1.6 and 12.5 cases per million adults, with 25-50% of this population affected by…
- Trial name
- EIGER (NCT01383083)
- Volunteers
- 42 people
- Sponsor
- Maryknoll Medical Center
Pulmonary Arterial Hypertension
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH…
- Trial name
- Compass-2 (NCT00303459)
- Testing
- bosentan
- Volunteers
- 334 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Children
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years.
- Trial name
- NCT00159913
- Testing
- Sildenafil citrate
- Where
- 41 sites in United States, Brazil and 15 more
- Volunteers
- 235 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the…
- Trial name
- STRIDE-3 (NCT00811018)
- Testing
- Sitaxsentan
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 1,192 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pressures in the blood vessels of the lungs that is not caused by another disease processes.
- Trial name
- TYEGER (NCT04280523)
- Testing
- ESR-specific PET scan
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center